| --- | --- | --- | |---------------------------|-------|-------| | | | | | | | | | Ironwood Q4 and Full Year | | | | | | | | | | | | 2021 Investor Update | | | | February 17, 2022 | | | Ironwood Introduction Matt Roache Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute well against our strategic priorities; the Company's strategy, business, fi ...

Leading in GI through Growth and Innovation J.P. Morgan Healthcare Conference January 12, 2022 PRESENTED BY Tom McCourt, CEO Ironwood Pharmaceuticals, Inc. Safe Harbor Statement 2 This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision and mission; our strategy, business, financial position and operations, including with respect to maximizing LINZESS® (linac ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q3 2021 Results Conference Call November 4, 2021 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Jason Rickard - Chief Operating Officer Conference Call Participants Hannah Adeoye - JPMorgan David Lebowitz - Morgan Stanley Tim Chiang - Northland Capital Operator Good morning. My name is Rob, and I will be your conference operator today. At this time, I would ...

| --- | --- | |------------------|-------| | | | | | | | | | | | | | | | | Ironwood Q3 2021 | | | | | | Earnings Update | | | November 4, 2021 | | Ironwood Introduction Matt Roache Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision and mission; our strategy, business, financial position and operations, including with respect to max ...

投资组合利率风险 - 公司投资组合主要为短期，利率立即变动1%不会对投资组合公允价值产生重大影响[250] 现金及投资风险 - 公司维持大量现金及现金等价物在金融机构，且超过联邦保险限额，无法保证未来投资不受市场价值不利变化影响[252] 可转换优先票据利率风险 - 公司可转换优先票据按固定利率计息，对利率变化风险极小，但未来若信用评级改善或情况变化，可能支付高于市场的利率[253] 可转换票据公允价值影响因素 - 公司可转换票据的公允价值取决于A类普通股的价格和波动性，会随普通股市场价格变化而增减[254] 可转换票据套期保值措施 - 为减少可转换票据转换对普通股潜在摊薄影响，公司针对2022年可转换票据开展可转换票据套期保值和票据套期保值认股权证，针对2024年和2026年可转换票据开展上限期权交易[255] 外币波动影响 - 公司没有预期以外币结算的重大货币资产或负债，预计不会受外币波动显著影响[257] 通货膨胀和价格变化影响 - 公司认为2021年和2020年截至9月30日的三个月和九个月内，通货膨胀和价格变化未对经营业绩产生重大影响[258]

| --- | --- | |-----------------|-------| | | | | | | | | | | Ironwood 2Q | 2021 | | | | | | | | Earnings Update | | | August 5, 2021 | | Ironwood Introduction Matt Roache Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision and mission; our strategy, business, financial position and operations, including with respect to maximizing L ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q2 2021 Earnings Conference Call August 5, 2021 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Jason Rickard - Chief Operating Officer Mike Shetzline - Chief Medical Officer Conference Call Participants Hannah Adeoye - JPMorgan Avatar Jones - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the Ironwood Pharmaceuticals 2Q 2021 Investor Update Call. At this time, all par ...

投资组合风险 - 公司投资组合主要为短期市场性证券，利率立即变动1%不会对投资组合的公允价值产生重大影响[241] - 公司维持大量现金及现金等价物在超过联邦保险限额的金融机构，无法保证未来投资不受市场价值不利变化影响[243] 可转换票据情况 - 公司可转换优先票据按固定利率计息，未来若信用评级提高或情况变化，可能支付相对市场更高的利率[244] - 公司可转换票据的公允价值取决于A类普通股的价格和波动性，会随普通股市场价格变化而增减[245] - 为减少可转换票据转换时对普通股潜在摊薄的影响，公司针对2022年可转换票据签订了可转换票据套期保值和票据套期保值认股权证，针对2024年和2026年可转换票据签订了上限期权[246] 外币及通胀影响 - 公司没有预期以外币结算的重大货币资产或负债，预计不会受到外币波动的重大影响[248] - 公司认为截至2021年6月30日和2020年的三个月和六个月内，通货膨胀和价格变化未对经营业绩产生重大影响[249]

| --- | --- | |------------------|-------| | | | | | | | | | | Ironwood 1Q 2021 | | | | | | Earnings Update | | Ironwood Introduction Meredith Kaya Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision and mission; our strategy, business, financial position and operations, including with respect to maximizing LINZESS® (linaclotide), b ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q1 2021 Earnings Conference Call May 6, 2021 8:30 AM ET Company Participants Meredith Kaya - VP, IR & Corporate Communications Thomas McCourt - President & Interim CEO Gina Consylman - Principal Accounting Officer, CFO, SVP & Treasurer Michael Shetzline - Chief Medical Officer, SVP & Head, Drug Development Conference Call Participants Jacob Hughes - Wells Fargo Securities Hannah Adeoye - JPMorgan Chase & Co. David Lebowitz - Morgan Stanley Operator Good day, and ...